Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Germany may miss COVID-19 vaccine donation goal, blames manufacturers

10/19/2021 | 10:11am EST

BERLIN, Oct 19 (Reuters) - Germany may miss its target to donate 100 million COVID-19 vaccine doses this year due to conditions imposed by manufacturers and delivery shortfalls, a health ministry official said in a letter to Brussels seen by Reuters.

The 100 million doses account for half of the total promised by European Union member states to poorer countries this year, according to the European Commission.

But on Oct. 19, the foreign office said Germany had only donated just over 17% of that amount.

In a letter on Monday to the European Commission's Health Emergency Preparedness and Response Authority (HERA), health ministry state secretary Thomas Steffen said there were "ongoing bureaucratic, logistical and legal problems" imposed by vaccine makers on EU countries wanting to donate surplus shots.

They make "a quick response to international requests for help almost impossible," Steffen added.

The letter is the strongest sign yet of the tensions between governments and drugmakers over donations. The EU and rich countries whose most vulnerable citizens have largely already been vaccinated are under heavy pressure from the World Health Organization to help deliver more doses to poorer nations, many of which have inoculated only a fraction of their populations.

"With vaccine surpluses in many member states increasing at present, we will soon be facing a situation of global allocation emergency," Steffen wrote. "Some countries could be forced to waste large volumes of valuable vaccines urgently needed in other parts of the world."

Obstacles include minimum sales prices, onerous compensation payments required of the recipient countries and restrictions on distributing to international organisations, he said.

Changes in expected delivery volumes and expiration dates of vaccine doses also make planning more difficult, he added.

Steffen said AstraZeneca and Johnson & Johnson could together only deliver up to 50 million doses of their COVID-19 vaccines this year, meaning Germany would also have to donate Pfizer/BioNTech and Moderna shots that are the mainstays of its vaccination drive.

In response, Johnson & Johnson said it would help countries with surplus doses to donate them to other countries, especially using the international COVAX facility, as long as the countries meet safety, legal, regulatory and logistical requirements.

The other manufacturers could not be immediately reached for comment.

EU countries have mostly promised to donate AstraZeneca and Johnson & Johnson vaccines. Many have restricted the use of these vaccines due to very rare cases of blood clotting.

Any shortfall in donations is likely to heighten the criticism of richer nations, which are rolling out boosters and inoculating teenagers considered a low-risk from COVID-19, while the pandemic rages elsewhere. (Reporting by Andreas Rinke Writing by Zuzanna Szymanska Editing by Mark Potter)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.14% 8411 Delayed Quote.14.84%
MODERNA, INC. 20.57% 329.63 Delayed Quote.215.53%
All news about MODERNA, INC.
11/26Vaccine companies testing efficacy against COVID-19 Omicron variant
AQ
11/26Moderna to Test Variant-Specific Vaccine Candidate
DJ
11/26Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
BU
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26Delta, Carnival fall; Moderna, Clorox rise
AQ
11/26Stocks tumble on new coronavirus variant fear
RE
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 170 M - -
Net cash 2021 12 747 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 6,93x
EV / Sales 2022 5,38x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 329,63 $
Average target price 272,53 $
Spread / Average Target -17,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548